COVID-19 associated neuropathy and myopathy in Germany.

• Conditions: U07.1; G73.7; G63.0; Polyneuropathy in infectious and parasitic diseases classified elsewhere; COVID-19, virus identified; Myopathy in other diseases classified elsewhere

• Registration Number: DRKS00021677
• Lead Sponsor: Klinik für Anästhesiologie, Intensiv- und Schmerzmedizin; Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Bochum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-05-11
• Study Completion: 2023-03-24
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

age = 18 years, voluntary participation, written informed consent for apparative examination, fluency in German language, positive PCR test for SARS-CoV-2 within the last 6 months, >14 days free on COVID-19-symptoms or two negative PCR tests

Exclusion Criteria

participants who are unable to provide information due to language barrier, psychological or somatic reasons, single contraindications for one of the performed tests (which are then spared)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of neuromuscular symptoms after COVID-19 (based on the initial online or telephone interview and in the course of up to 12 months)

Secondary Outcome Measures

Name	Time	Method
Prevalence of functional and/or morphological affection of small and large nerve fibers and muscles after COVID-19 (based on neurophysiological examinations within 6 months after COVID-19 and possibly 6 months after the initial examination)